Crypto spot volume fell to $1.59 trillion in November, marking its weakest month since June as sentiment and liquidity softened.]]>Crypto spot volume fell to $1.59 trillion in November, marking its weakest month since June as sentiment and liquidity softened.]]>

Crypto Spot Volume Drops to $1.59T as Market Activity Fades in November

  • Crypto spot volume sank to $1.59T in November as broader market liquidity thinned and investor activity cooled sharply.
  • Macroeconomic pressure and ETF outflows deepened market weakness, leaving traders cautious after a wave of liquidations hit multiple assets.

November’s crypto spot volume retreated to $1.59 trillion, the lowest reading since June. With liquidity shrinking by around 26.7% from the previous month, the broader market moved with a noticeably softer tone.

At the same time, public sentiment also slumped, with the Fear and Greed index reaching 20, falling within the “Fear” category, while the average Crypto RSI dropped to 34.52, already in the oversold area.

Source: The Block

Crypto Spot Market Faces Pressure as Macro Signals Turn Harsh

Looking at the dynamics of the past few weeks, this pattern appears to be beginning to be reflected. Last November, we reported that the decline in the S&P 500 index and the Nasdaq’s reversal brought new pressure to the crypto market. On the other hand, these movements triggered a wave of concern as investors began to take defensive measures.

The jobs report released by the Bureau of Labor Statistics that month also set off a wave of liquidations, leaving the market in an even more fragile position. When factors like these converge in a single period, the effects are immediately felt on the crypto spot market, which is usually a barometer of daily activity.

Furthermore, outflows from spot ETFs also added to the drop in volume, as several large players pulled back and reduced liquidity. The market turned quieter than many anticipated. Still, a few analysts note that declines like this can be a period when investors rethink their positioning, especially after major assets such as Bitcoin lose momentum.

On the other hand, traders monitoring technical conditions are beginning to see some interesting signals. While not entirely comforting, the oversold area on the Crypto RSI is often considered a zone that offers opportunities for short-term recovery. However, a fear-ridden market makes buying difficult.

For now, the main focus remains on how crypto spot will move in the coming weeks. This is because weakening volumes are usually an early indicator of whether the market is ready to enter a new phase or is simply remaining in a sluggish pattern.

]]>
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23